🎉 M&A multiples are live!
Check it out!

Northwest Biotherapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Northwest Biotherapeutics and similar public comparables like GSK India, Prescient Therapeutics, and CSL.

Northwest Biotherapeutics Overview

About Northwest Biotherapeutics

Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.


Founded

1998

HQ

United States of America
Employees

25

Website

nwbio.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$361M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Northwest Biotherapeutics Financials

Northwest Biotherapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Northwest Biotherapeutics achieved revenue of $1.4M and an EBITDA of -$74.0M.

Northwest Biotherapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Northwest Biotherapeutics valuation multiples based on analyst estimates

Northwest Biotherapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $1.9M $1.4M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$55.6M -$74.0M XXX XXX XXX
EBITDA Margin -2879% -5352% XXX XXX XXX
Net Profit -$105M -$62.6M XXX XXX XXX
Net Margin -5436% -4530% XXX XXX XXX
Net Debt $14.6M $38.7M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Northwest Biotherapeutics Stock Performance

As of April 15, 2025, Northwest Biotherapeutics's stock price is $0.

Northwest Biotherapeutics has current market cap of $296M, and EV of $361M.

See Northwest Biotherapeutics trading valuation data

Northwest Biotherapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$361M $296M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Northwest Biotherapeutics Valuation Multiples

As of April 15, 2025, Northwest Biotherapeutics has market cap of $296M and EV of $361M.

Northwest Biotherapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Northwest Biotherapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Northwest Biotherapeutics and 10K+ public comps

Northwest Biotherapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $361M XXX XXX XXX
EV/Revenue 261.1x XXX XXX XXX
EV/EBITDA -4.9x XXX XXX XXX
P/E -3.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -6.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Northwest Biotherapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Northwest Biotherapeutics Valuation Multiples

Northwest Biotherapeutics's NTM/LTM revenue growth is n/a

Northwest Biotherapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $2.7M for the same period.

Over next 12 months, Northwest Biotherapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Northwest Biotherapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Northwest Biotherapeutics and other 10K+ public comps

Northwest Biotherapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -28% XXX XXX XXX XXX
EBITDA Margin -5352% XXX XXX XXX XXX
EBITDA Growth 33% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $2.7M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 2388% XXX XXX XXX XXX
R&D Expenses to Revenue 2524% XXX XXX XXX XXX
Opex to Revenue 4912% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Northwest Biotherapeutics Public Comps

See public comps and valuation multiples for Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
CSL XXX XXX XXX XXX XXX XXX
Imugene XXX XXX XXX XXX XXX XXX
Prescient Therapeutics XXX XXX XXX XXX XXX XXX
GSK India XXX XXX XXX XXX XXX XXX
AstraZeneca India XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Northwest Biotherapeutics M&A and Investment Activity

Northwest Biotherapeutics acquired  XXX companies to date.

Last acquisition by Northwest Biotherapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Northwest Biotherapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Northwest Biotherapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Northwest Biotherapeutics

When was Northwest Biotherapeutics founded? Northwest Biotherapeutics was founded in 1998.
Where is Northwest Biotherapeutics headquartered? Northwest Biotherapeutics is headquartered in United States of America.
How many employees does Northwest Biotherapeutics have? As of today, Northwest Biotherapeutics has 25 employees.
Is Northwest Biotherapeutics publicy listed? Yes, Northwest Biotherapeutics is a public company listed on PINX.
What is the stock symbol of Northwest Biotherapeutics? Northwest Biotherapeutics trades under NWBO ticker.
When did Northwest Biotherapeutics go public? Northwest Biotherapeutics went public in 2001.
Who are competitors of Northwest Biotherapeutics? Similar companies to Northwest Biotherapeutics include e.g. CSL, Imugene, Prescient Therapeutics, GSK India.
What is the current market cap of Northwest Biotherapeutics? Northwest Biotherapeutics's current market cap is $296M
What is the current revenue growth of Northwest Biotherapeutics? Northwest Biotherapeutics revenue growth between 2023 and 2024 was -28%.
Is Northwest Biotherapeutics profitable? Yes, Northwest Biotherapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.